Gemcitabine as adjuvant chemotherapy following complete resection for pancreatic cancer did not improve overall survival when compared with standard chemotherapy with fluorouracil plus folinic acid in a randomized, controlled, open-label phase III trial, according to a report in the Sept. 8 issue of JAMA. In what they described as "the largest ever adjuvant trial conducted in pancreatic cancer," median overall survival and median progression-free survival were essentially the same between the two...